The Cancer Chemotherapy Drug Etoposide (VP-16) Induces Proinflammatory Cytokine Production and Sickness Behavior–like Symptoms in a Mouse Model of Cancer Chemotherapy–Related Symptoms
Restricted accessResearch articleFirst published online October, 2006
The Cancer Chemotherapy Drug Etoposide (VP-16) Induces Proinflammatory Cytokine Production and Sickness Behavior–like Symptoms in a Mouse Model of Cancer Chemotherapy–Related Symptoms
Cancer chemotherapy–related symptoms such as fatigue, malaise, loss of interest in social activities, difficulty concentrating, and changes in sleep patterns can lead to treatment delays, dose reductions, or termination and have a profound effect on the physical, psychosocial, and economic aspects of quality of life. Clinicians have long suspected that these symptoms are similar to those associated with “sickness behavior,” which is triggered by the production of the inflammatory cytokines IL-1β, TNF-α, and IL-6 by macrophages and other cells of the innate immune system in response to immune challenge. The p38 mitogen-activated protein kinase (p38 MAPK) plays a central role in the production of these cytokines and consequently the induction of sickness behavior. Several cancer chemotherapy drugs have been shown to activate p38 MAPK, but whether these drugs can also induce the production of inflammatory cytokines to cause sickness behavior is unknown. The aim of this study was to determine whether the cancer chemotherapy drug etoposide (VP-16), which is known to activate p38 MAPK, could induce inflammatory cytokine production by murine macrophages and sickness-like behaviors when injected into mice. VP-16 activated p38 MAPK and induced IL-6 production in murine macrophages in a p38 MAPK– dependent manner. VP-16 administration rapidly increased serum levels of IL-6 in healthy mice and induced sickness-like behaviors as evidenced by a decrease in food intake, body weight, hemoglobin level, and voluntary wheel-running activity. These findings support the idea that the induction of IL-1β, TNF-α, and IL-6 by cancer chemotherapy drugs underlies the fatigue and associated symptoms experienced by people undergoing cancer chemotherapy.
Abbas, A. K., & Lichtman, A. H. (2003). Innate immunity. Philadelphia, PA: Saunders.
2.
Ahlberg, K., Ekman, T., Gaston-Johansson, F., & Mock, V. (2003). Assessment and management of cancer-related fatigue in adults. Lancet, 362(9384), 640-650.
3.
Badger, A. M., Bradbeer, J. N., Votta, B., Lee, J. C., Adams, J. L., & Griswold, D. E. (1996). Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. Journal of Pharmacology & Experimental Therapeutics, 279(3), 1453-1461.
4.
Ben-Levy, R., Hooper, S., Wilson, R., Paterson, H. F., & Marshall, C. J. (1998). Nuclear export of the stress-activated protein kinase p38 mediated by its substrate MAPKAP kinase-2. Current Biology, 8(19), 1049-1057.
5.
Berger, A. (2003). Treating fatigue in cancer patients. Oncologist, 8(Suppl. 1), 10-14.
6.
Berger, A. M. (1998). Patterns of fatigue and activity and rest during adjuvant breast cancer chemotherapy. Oncology Nursing Forum, 25(1), 51-62.
7.
Bernard, S., Gill, P., Rosen, P., Gavigan, M., Steagall, A., Ellingham, E., et al. (1991). A phase I trial of alpha-interferon in combination with pentostatin in hematologic malignancies. Medical & Pediatric Oncology, 19(4), 276-282.
8.
Blohmer, J. U., Dunst, J., Harrison, L., Johnston, P., Khayat, D., Ludwig, H., et al. (2005). Cancer-related anemia: Biological findings, clinical implications and impact on quality of life. Oncology, 68(Suppl. 1), 12-21.
9.
Bluthe, R. M., Laye, S., Michaud, B., Combe, C., Dantzer, R., & Parnet, P. (2000). Role of interleukin-1beta and tumour necrosis factor-alpha in lipopolysaccharide-induced sickness behaviour: A study with interleukin-1 type I receptor-deficient mice. European Journal of Neuroscience, 12(12), 4447-4456.
10.
Bluthe, R. M., Michaud, B., Poli, V., & Dantzer, R. (2000). Role of IL-6 in cytokine-induced sickness behavior: A study with IL-6 deficient mice. Physiology & Behavior, 70(3-4), 367-373.
11.
Bower, J. E., Ganz, P. A., Aziz, N., & Fahey, J. L. (2002). Fatigue and proinflammatory cytokine activity in breast cancer survivors. Psychosomatic Medicine, 64(4), 604-611.
12.
Branger, J., van den Blink, B., Weijer, S., Madwed, J., Bos, C. L., Gupta, A., et al. (2002). Anti-inflammatory effects of a p38 mitogen-activated protein kinase inhibitor during human endotoxemia. Journal of Immunology, 168(8), 4070-4077.
13.
Cahlin, C., Korner, A., Axelsson, H., Wang, W., Lundholm, K., & Svanberg, E. (2000). Experimental cancer cachexia: The role of host-derived cytokines interleukin (IL)-6, IL-12, interferon gamma, and tumor necrosis factor alpha evaluated in gene knockout, tumor-bearing mice on C57 Bl background and eicosanoid-dependent cachexia. Cancer Research, 60(19), 5488-5493.
14.
Chao, C. C., DeLaHunt, M., Hu, S., Close, K., & Peterson, P. K. (1992). Immunologically mediated fatigue: A murine model. Clinical Immunology & Immunopathology, 64(2), 161-165.
15.
Dantzer, R. (2001). Cytokine-induced sickness behavior: Mechanisms and implications. Annals of the New York Academy of Sciences, 933, 222-234.
16.
Dantzer, R., Konsman, J. P., Bluthe, R. M., & Kelley, K. W. (2000). Neural and humoral pathways of communication from the immune system to the brain: parallel or convergent?Autonomic Neuroscience, 85(1-3), 60-65.
17.
Ding, A. H., Porteu, F., Sanchez, E., & Nathan, C. F. (1990). Shared actions of endotoxin and taxol on TNF receptors and TNF release. Science, 248(4953), 370-372.
18.
Escalante, C. P. (2003). Treatment of cancer-related fatigue: An update. Supportive Care in Cancer, 11(2), 79-83.
19.
Haldar, S., Basu, A., & Croce, C. M. (1997). Bcl2 is the guardian of microtubule integrity. Cancer Research, 57(2), 229-233.
20.
Hentze, M. W., Muckenthaler, M. U., & Andrews, N. C. (2004). Balancing acts: Molecular control of mammalian iron metabolism. Cell, 117(3), 285-297.
21.
Hill, A. G., Siegel, J., Rounds, J., & Wilmore, D. W. (1997). Metabolic responses to interleukin-1: Centrally and peripherally mediated. Annals of Surgery, 225(3), 246-251.
22.
Jacobsen, P. B., Donovan, K. A., & Weitzner, M. A. (2003). Distinguishing fatigue and depression in patients with cancer. Seminars in Clinical Neuropsychiatry, 8(4), 229-240.
23.
Kemna, E. H., Pickkers, P., Nemeth, E., van der Hoeven, H., & Swinkels, D. (2005). Time-course analysis of hepcidin, serum iron, and plasma cytokine levels in humans injected with LPS. Blood, 106(5), 1864-1866.
24.
Kent, S., Bret-Dibat, J. L., Kelley, K. W., & Dantzer, R. (1996). Mechanisms of sickness-induced decreases in food-motivated behavior. Neuroscience & Biobehavioral Reviews, 20(1), 171-175.
25.
Konsman, J. P & Dantzer, R. (2001). How the immune and nervous systems interact during disease associated anorexia. Nutrition, 17 (7-8), 664-668.
26.
Kozak, W., Kluger, M. J., Soszynski, D., Conn, C. A., Rudolph, K., Leon, L. R., et al. (1998). IL-6 and IL-1 beta in fever. Studies using cytokine-deficient (knockout) mice. Annals of the New York Academy of Sciences, 856, 33-47.
27.
Laufer, S. A., Wagner, G. K., Kotschenreuther, D. A., & Albrecht, W. (2003). Novel substituted pyridinyl imidazoles as potent anticytokine agents with low activity against hepatic cytochrome P450 enzymes. Journal of Medicinal Chemistry, 46(15), 3230-3244.
28.
Laviano, A., Cangiano, C., Fava, A., Muscaritoli, M., Mulieri, G., & Rossi Fanelli, F. (1999). Peripherally injected IL-1 induces anorexia and increases brain tryptophan concentrations. Advances in Experimental Medicine & Biology, 467, 105-108.
29.
Lee, B. N., Dantzer, R., Langley, K. E., Bennett, G. J., Dougherty, P. M., Dunn, A. J., et al. (2004). A cytokine-based neuroimmunologic mechanism of cancer-related symptoms. Neuroimmunomodulation, 11(5), 279-292.
30.
Lou, J., Ythier, A., Burger, D., Zheng, L., Juillard, P., Lucas, R., et al. (1997). Modulation of soluble and membrane-bound TNF induced phenotypic and functional changes of human brain microvascular endothelial cells by recombinant TNF binding protein I. Journal of Neuroimmunology, 77(1), 107-115.
31.
Lyczak, J. (2004). Innate immunity. In J. B. Lyczak., G. B. Pier, & L. M. Wetzler (Eds.), Immunology, infection, and immunity. Washington, DC: ASM Press.
32.
Manzullo, E., Liu, W., & Escalante, C. (2003). Treatment for cancer-related fatigue: An update. Expert Review of Anticancer Therapy, 3(1), 99-106.
33.
McCarthy, D. O. (2000). Tumor necrosis factor alpha and interleukin-6 have differential effects on food intake and gastric emptying in fasted rats. Research in Nursing & Health, 23(3), 222-228.
34.
Mercadante, S., Gebbia, V., Marrazzo, A., & Filosto, S. (2000). Anaemia in cancer: Pathophysiology and treatment. Cancer Treatment Reviews, 26(4), 303-311.
35.
Moos, P. J., & Fitzpatrick, F. A. (1998). Taxane-mediated gene induction is independent of microtubule stabilization: Induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proceedings of the National Academy of Science U S A, 95(7), 3896-3901.
36.
Moos, P. J., Muskardin, D. T., & Fitzpatrick, F. A. (1999). Effect of taxol and taxotere on gene expression in macrophages: Induction of the prostaglandin H synthase-2 isoenzyme. Journal of Immunology, 162(1), 467-473.
37.
Nishimoto, N., Sasai, M., Shima, Y., Nakagawa, M., Matsumoto, T., Shirai, T., et al. (2000). Improvement in Castleman's disease by humanized anti-interleukin-6 receptor antibody therapy. Blood, 95(1), 56-61.
38.
Olson, J. M., & Hallahan, A. R. (2004). p38 MAP kinase: A convergence point in cancer therapy. Trends in Molecular Medicine, 10(3), 125-129.
39.
Ottenweller, J. E., Natelson, B. H., Gause, W. C., Carroll, K. K., Beldowicz, D., Zhou, X. D., et al. (1998). Mouse running activity is lowered by Brucella abortus treatment: A potential model to study chronic fatigue. Physiology & Behavior, 63(5), 795-801.
40.
Pasparakis, M., Alexopoulou, L., Episkopou, V., & Kollias, G. (1996). Immune and inflammatory responses in TNF alpha deficient mice: A critical requirement for TNF alpha in the formation of primary B cell follicles, follicular dendritic cell networks and germinal centers, and in the maturation of the humoral immune response. Journal of Experimental Medicine, 184(4), 1397-1411.
41.
Petersen, A. M., & Pedersen, B. K. (2005). The anti-inflammatory effects of exercise. The Journal of Applied Physiology, 98(4), 1154-1162.
42.
Poli, V., Balena, R., Fattori, E., Markatos, A., Yamamoto, M., Tanaka, H., et al. (1994). Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO Journal, 13(5), 1189-1196.
43.
Purswani, M. U., Eckert, S. J., Arora, H. K., & Noel, G. J. (2002). Effect of ciprofloxacin on lethal and sublethal challenge with endotoxin and on early cytokine responses in a murine in vivo model. Journal of Antimicrobial Chemotherapy, 50(1), 51-58.
44.
Pusztai, L., Mendoza, T. R., Reuben, J. M., Martinez, M. M., Willey, J. S., Lara, J., et al. (2004). Changes in plasma levels of inflammatory cytokines in response to paclitaxel chemotherapy. Cytokine, 25(3), 94-102.
45.
Schiepers, O. J., Wichers, M. C., & Maes, M. (2005). Cytokines and major depression. Progress in Neuro-psychopharmacology & Biological Psychiatry, 29(2), 201-217.
46.
Schwartz, A. L. (1998). Patterns of exercise and fatigue in physically active cancer survivors. Oncology Nursing Forum, 25(3), 485-491.
47.
Schwartz, A. L., Nail, L. M., Chen, S., Meek, P., Barsevick, A. M., King, M. E., et al. (2000). Fatigue patterns observed in patients receiving chemotherapy and radiotherapy. Cancer Investigation, 18(1), 11-19.
48.
Sheng, W. S., Hu, S., Lamkin, A., Peterson, P. K., & Chao, C. C. (1996). Susceptibility to immunologically mediated fatigue in C57BL/6 versus Balb/c mice. Clinical Immunology & Immunopathology, 81(2), 161-167.
49.
Stasi, R., Abriani, L., Beccaglia, P., Terzoli, E., & Amadori, S. (2003). Cancer-related fatigue: Evolving concepts in evaluation and treatment. Cancer, 98(9), 1786-1801.
50.
ten Tije, A. J., Smorenburg, C. H., Seynaeve, C., Sparreboom, A., Schothorst, K. L., Kerkhofs, L. G., et al. (2004). Weekly paclitaxel as first-line chemotherapy for elderly patients with metastatic breast cancer. A multicentre phase II trial. European Journal of Cancer, 40(3), 352-357.
51.
Tisdale, M. J. (2002). Cachexia in cancer patients. Nature Reviews Cancer, 2(11), 862-871.
52.
Tisdale, M. J. (2004). Cancer cachexia. Langenbecks Archives of Surgery, 389(4), 299-305.
53.
Trikha, M., Corringham, R., Klein, B., & Rossi, J. F. (2003). Targeted anti-interleukin-6 monoclonal antibody therapy for cancer: A review of the rationale and clinical evidence. Clinical Cancer Research, 9(13), 4653-4665.
54.
White, C. M., Martin, B. K., Lee, L. F., Haskill, J. S., & Ting, J. P. (1998). Effects of paclitaxel on cytokine synthesis by unprimed human monocytes, T lymphocytes, and breast cancer cells. Cancer Immunology, Immunotherapy, 46(2), 104-112.
55.
Zaks-Zilberman, M., Zaks, T. Z., & Vogel, S. N. (2001). Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. Cytokine, 15(3), 156-165.
56.
Zhou, W., Jiang, Z. W., Tian, J., Jiang, J., Li, N., & Li, J. S. (2003). Role of NF-kappaB and cytokine in experimental cancer cachexia. World Journal of Gastroenterology, 9(7), 1567-1570.
